De Serres Gaston, Boulianne Nicole, Duval Bernard, Rochette Louis, Grenier Jean Luc, Roussel Renée, Donaldson Danièle, Tremblay Michèle, Toth Eveline, Ménard Suzanne, Landry Monique, Robert Yves
Direction de la santé publique de Québec, Que, Québec, Canada G1E 7G9.
Vaccine. 2003 Jun 2;21(19-20):2346-53. doi: 10.1016/s0264-410x(03)00095-1.
We assessed the occurrence of oculo-respiratory syndrome (ORS) following two influenza vaccines: Fluviral (Shire Biologics) or Vaxigrip (Aventis Pasteur). ORS was identified amongst 5.3 and 4.6% of recipients, respectively (P=0.54). With both vaccines, the risk of ORS was much greater in individuals who had ORS the previous year (2000) than in those without such history. In multivariate analysis, the odds ratio for ORS for patients with a prior history of ORS varied between 9.4 and 9.6 (P<0.001) whereas that comparing Fluviral and Vaxigrip varied between 1.5 and 1.9 (P=0.02-0.05). ORS is an adverse event that is present with more than one vaccine and may be present with any influenza vaccines to a greater or lesser degree.
我们评估了两种流感疫苗（弗卢万（夏尔生物制品公司）或维克佐德（赛诺菲巴斯德公司））接种后眼-呼吸综合征（ORS）的发生情况。接种者中ORS的发生率分别为5.3%和4.6%（P = 0.54）。对于这两种疫苗，前一年（2000年）患过ORS的个体发生ORS的风险比未患过该病的个体要高得多。在多变量分析中，既往有ORS病史的患者发生ORS的优势比在9.4至9.6之间（P < 0.001），而比较弗卢万和维克佐德的优势比在1.5至1.9之间（P = 0.02 - 0.05）。ORS是一种在不止一种疫苗接种后出现的不良事件，并且在任何流感疫苗接种后都可能或多或少地出现。
